COHEN-ADAD, Julien, Eva ALONSO-ORTIZ, Mihael ABRAMOVIC, Carina ARNEITZ, Nicole ATCHESON, Laura BARLOW, Robert L BARRY, Markus BARTH, Marco BATTISTON, Christian BÜCHEL, Matthew BUDDE, Virginie CALLOT, Anna J E COMBES, Benjamin De LEENER, Maxime DESCOTEAUX, Paulo Loureiro de SOUSA, Marek DOSTÁL, Julien DOYON, Adam DVORAK, Falk EIPPERT, Karla R EPPERSON, Kevin S EPPERSON, Patrick FREUND, Jürgen FINSTERBUSCH, Alexandru FOIAS, Michela FRATINI, Issei FUKUNAGA, Claudia A M Gandini WHEELER-KINGSHOTT, Giancarlo GERMANI, Guillaume GILBERT, Federico GIOVE, Charley GROS, Francesco GRUSSU, Akifumi HAGIWARA, Pierre-Gilles HENRY, Tomáš HORÁK, Masaaki HORI, James JOERS, Kouhei KAMIYA, Haleh KARBASFOROUSHAN, Miloš KEŘKOVSKÝ, Ali KHATIBI, Joo-Won KIM, Nawal KINANY, Hagen KITZLER, Shannon KOLIND, Yazhuo KONG, Petr KUDLIČKA, Paul KUNTKE, Nyoman D KURNIAWAN, Slawomir KUSMIA, René LABOUNEK, Maria Marcella LAGANÀ, Cornelia LAULE, Christine S LAW, Christophe LENGLET, Tobias LEUTRITZ, Yaou LIU, Sara LLUFRIU, Sean MACKEY, Eloy MARTINEZ-HERAS, Loan MATTERA, Igor NESTRASIL, Kristin P O GRADY, Nico PAPINUTTO, Daniel PAPP, Deborah PARETO, Todd B PARRISH, Anna PICHIECCHIO, Ferran PRADOS, Àlex ROVIRA, Marc J RUITENBERG, Rebecca S SAMSON, Giovanni SAVINI, Maryam SEIF, Alan C SEIFERT, Alex K SMITH, Seth A SMITH, Zachary A SMITH, Elisabeth SOLANA, Yuichi SUZUKI, George TACKLEY, Alexandra TINNERMANN, Jan VALOŠEK, Dimitri Van De VILLE, Marios C YIANNAKAS, Kenneth A Weber II, Nikolaus WEISKOPF, Richard G WISE, Patrik O WYSS and Junqian XU. Generic acquisition protocol for quantitative MRI of the spinal cord. Nature Protocols. Berlin: Nature Research, 2021, vol. 16, No 10, p. 4611-4632. ISSN 1754-2189. Available from: https://dx.doi.org/10.1038/s41596-021-00588-0.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Generic acquisition protocol for quantitative MRI of the spinal cord
Authors COHEN-ADAD, Julien (guarantor), Eva ALONSO-ORTIZ, Mihael ABRAMOVIC, Carina ARNEITZ, Nicole ATCHESON, Laura BARLOW, Robert L BARRY, Markus BARTH, Marco BATTISTON, Christian BÜCHEL, Matthew BUDDE, Virginie CALLOT, Anna J E COMBES, Benjamin De LEENER, Maxime DESCOTEAUX, Paulo Loureiro de SOUSA, Marek DOSTÁL (203 Czech Republic, belonging to the institution), Julien DOYON, Adam DVORAK, Falk EIPPERT, Karla R EPPERSON, Kevin S EPPERSON, Patrick FREUND, Jürgen FINSTERBUSCH, Alexandru FOIAS, Michela FRATINI, Issei FUKUNAGA, Claudia A M Gandini WHEELER-KINGSHOTT, Giancarlo GERMANI, Guillaume GILBERT, Federico GIOVE, Charley GROS, Francesco GRUSSU, Akifumi HAGIWARA, Pierre-Gilles HENRY, Tomáš HORÁK (203 Czech Republic, belonging to the institution), Masaaki HORI, James JOERS, Kouhei KAMIYA, Haleh KARBASFOROUSHAN, Miloš KEŘKOVSKÝ (203 Czech Republic, belonging to the institution), Ali KHATIBI, Joo-Won KIM, Nawal KINANY, Hagen KITZLER, Shannon KOLIND, Yazhuo KONG, Petr KUDLIČKA (203 Czech Republic, belonging to the institution), Paul KUNTKE, Nyoman D KURNIAWAN, Slawomir KUSMIA, René LABOUNEK, Maria Marcella LAGANÀ, Cornelia LAULE, Christine S LAW, Christophe LENGLET, Tobias LEUTRITZ, Yaou LIU, Sara LLUFRIU, Sean MACKEY, Eloy MARTINEZ-HERAS, Loan MATTERA, Igor NESTRASIL, Kristin P O GRADY, Nico PAPINUTTO, Daniel PAPP, Deborah PARETO, Todd B PARRISH, Anna PICHIECCHIO, Ferran PRADOS, Àlex ROVIRA, Marc J RUITENBERG, Rebecca S SAMSON, Giovanni SAVINI, Maryam SEIF, Alan C SEIFERT, Alex K SMITH, Seth A SMITH, Zachary A SMITH, Elisabeth SOLANA, Yuichi SUZUKI, George TACKLEY, Alexandra TINNERMANN, Jan VALOŠEK, Dimitri Van De VILLE, Marios C YIANNAKAS, Kenneth A Weber II, Nikolaus WEISKOPF, Richard G WISE, Patrik O WYSS and Junqian XU.
Edition Nature Protocols, Berlin, Nature Research, 2021, 1754-2189.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 10609 Biochemical research methods
Country of publisher Germany
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 17.021
RIV identification code RIV/00216224:14110/21:00120181
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1038/s41596-021-00588-0
UT WoS 000685389200002
Keywords in English quantitative MRI; spinal cord
Tags 14110216, CF MAFIL, podil, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 14/3/2022 10:11.
Abstract
Quantitative spinal cord (SC) magnetic resonance imaging (MRI) presents many challenges, including a lack of standardized imaging protocols. Here we present a prospectively harmonized quantitative MRI protocol, which we refer to as the spine generic protocol, for users of 3T MRI systems from the three main manufacturers: GE, Philips and Siemens. The protocol provides guidance for assessing SC macrostructural and microstructural integrity: T1-weighted and T2-weighted imaging for SC cross-sectional area computation, multi-echo gradient echo for gray matter cross-sectional area, and magnetization transfer and diffusion weighted imaging for assessing white matter microstructure. In a companion paper from the same authors, the spine generic protocol was used to acquire data across 42 centers in 260 healthy subjects. The key details of the spine generic protocol are also available in an open-access document that can be found at https://github.com/spine-generic/ protocols. The protocol will serve as a starting point for researchers and clinicians implementing new SC imaging initiatives so that, in the future, inclusion of the SC in neuroimaging protocols will be more common. The protocol could be implemented by any trained MR technician or by a researcher/clinician familiar with MRI acquisition.
Links
NV18-04-00159, research and development projectName: Využití pokročilých magneticko-rezonančních technik k odhalení patofyziologie a zlepšení diagnostiky a praktického managementu degenerativní komprese krční míchy
Investor: Ministry of Health of the CR
681094, interní kód MUName: NISCI - Antibodies against Nogo-A to enhance plasticity, regeneration and functional recovery after acute spinal cord injury, a multicenter European randomized double blinded placebo controlled phase II clinical proof of concept trial (Acronym: NISCI)
Investor: European Union, Health, demographic change and wellbeing (Societal Challenges)
PrintDisplayed: 26/4/2024 09:35